Get started
Author

Jessica E. Louw

Observed names: J. Louw, Jessica Louw, Louw, Jessica
OpenAlex ID: A5112211811
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
2016 · Howard I. Scher, David Lu, et al. · JAMA Oncology · 658
PDF
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
2016 · Howard I. Scher, Ryon P. Graf, et al. · European Urology · 186
PDF
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2017 · Howard I. Scher, Ryon P. Graf, et al. · Cancer Research · 136
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
2015 · Himisha Beltran, Adam Jendrisak, et al. · Clinical Cancer Research · 136
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
2016 · Archana Anantharaman, Terence Friedlander, et al. · BMC Cancer · 105
PDF
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
2015 · Elizabeth A Punnoose, Roberta Ferraldeschi, et al. · British Journal of Cancer · 95
PDF
Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2017 · Daniel J. Boffa, Ryon P. Graf, et al. · Cancer Epidemiology Biomarkers & Prevention · 71
Phenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancer
2016 · Andrew S. McDaniel, Roberta Ferraldeschi, et al. · British Journal of Urology · 68
Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer
2019 · Simpa S. Salami, Udit Singhal, et al. · JCO Precision Oncology · 32
Androgen receptor expression on circulating tumor cells in metastatic breast cancer
2017 · Takeo Fujii, James M. Reuben, et al. · PLoS ONE · 22
PDF
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
2016 · Archana Anantharaman, Terence W. Friedlander, et al. · Journal of Clinical Oncology · 13
Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells
2015 · David Lu, Ryon P. Graf, et al. · Journal of Circulating Biomarkers · 11
PDF
CK- and small nuclear size circulating tumor cell (CTCs) phenotypes in metastatic castration-resistant prostate cancer (mCRPC).
2014 · Roberta Ferraldeschi, Andrew McDaniel, et al. · Journal of Clinical Oncology · 6
Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in progressive metastatic castration resistant prostate cancer (mCRPC).
2014 · Ryan Dittamore, Jessica Louw, et al. · Journal of Clinical Oncology · 6
Sequential monitoring and characterization of circulating tumor cells (CTCs) using the epic sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with recently approved therapeutics.
2014 · Roberta Ferraldeschi, Rachel Krupa, et al. · Journal of Clinical Oncology · 6
AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy.
2016 · Howard I. Scher, Ryon Graf, et al. · Journal of Clinical Oncology · 5
Phenotypic characterization of circulating tumor cells (CTCs) from neuroendocrine prostate cancer (NEPC) and metastatic castration-resistant prostate cancer (mCRPC) patients to identify a novel diagnostic algorithm for the presence of NEPC.
2015 · Himisha Beltran, Adam Jendrisak, et al. · Journal of Clinical Oncology · 5
Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
2015 · Howard I. Scher, Jessica Louw, et al. · Journal of Clinical Oncology · 5
CTC phenotype classifier to identify mCRPC patients (pts) with high genomic instability CTCs and to predict failure of androgen ecreptor signaling (AR Tx) and taxane (T) systemic therapies.
2016 · Howard I. Scher, Adam Jendrisak, et al. · Journal of Clinical Oncology · 4
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) and white blood cells (WBCs) in muscle invasive and metastatic bladder cancer patients.
2016 · Archana Anantharaman, Terence W. Friedlander, et al. · Journal of Clinical Oncology · 4
Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients.
2016 · Howard I. Scher, Ryon Graf, et al. · Journal of Clinical Oncology · 4
Characteristics of De Novo Resistance to Androgen Targeting Therapeutics (Ar Tx) Through Circulating Tumor Cells (Ctcs) Analysis in Metastatic Castration Resistant Prostate Cancer (Mcrpc) Patients
2014 · R.M. Bambury, J. Louw, et al. · Annals of Oncology · 4
Heterogeneity of prostate-specific membrane antigen (PSMA) expression in classic and apoptotic circulating tumor cells (CTC) in metastatic castration-resistant prostate cancer (mCRPC).
2014 · Karen A. Autio, Aseem Anand, et al. · Journal of Clinical Oncology · 3
PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study
2016 · R. Graf, D. Lu, et al. · Annals of Oncology · 1
Programmed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter cohort.
2016 · Daniel J Boffa, Jorge J. Nieva, et al. · Journal of Clinical Oncology · 1
Works count: 66
Citation count: 1,594
H-index: 11
I10-index: 12
Year
Topic
Type